Loading…

MiOXSYS ® and OxiSperm ® II assays appear to provide no clinical utility for determining oxidative stress in human sperm-results from repeated semen collections

Oxidative stress in semen contributes up to 80% of all infertility diagnosis. Diagnostics to measure oxidative stress in semen was recently added to the 6th edition WHO methods manual, although diagnostic predictive values need to be interpreted with caution as there are still several research quest...

Full description

Saved in:
Bibliographic Details
Published in:Andrology (Oxford) 2023-11, Vol.11 (8), p.1566-1578
Main Authors: Castleton, Patience, Gyawali, Prabin, Mathews, Nicola, Mutuku, Shadrack Mulinge, Sharkey, David James, McPherson, Nicole Olivia
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Oxidative stress in semen contributes up to 80% of all infertility diagnosis. Diagnostics to measure oxidative stress in semen was recently added to the 6th edition WHO methods manual, although diagnostic predictive values need to be interpreted with caution as there are still several research questions yet to be answered. To determine the natural fluctuations in semen redox indicators (MiOXSYS and OxiSperm II) within and between men and their association with markers of sperm oxidative stress. Total, 118 repeat semen samples from 31 generally healthy men aged 18-45 years, over 6 months. Standard semen analysis as per 5th WHO manual. Semen redox levels measured via MiOXSYS and OxiSperm II. Additional attributes of sperm quality; HBA binding assay and sperm hyperactivation and oxidative stress; DNA fragmentation (Halo Sperm) and lipid peroxidation (BODIPY™ 581/591 C11) were assessed. Samples with high redox-potential (MiOXSYS ≥1.47 sORP/10 sperm/ml) had lower sperm, motility, morphology and higher DNA fragmentation (P  0.05). Fluctuations in semen redox levels varied greater between men than within men over the study period. Neither MiOXSYS nor OxiSperm II assays were predictive of sperm function or sperm oxidative stress. This was likely due at least in part to limited understanding of their biochemistry and clinical application. As a result, these assays seem to provide no additional clinical utility beyond that of a standard semen analysis, highlighting the imperative for the development of new robust point-of-care devices for accurately determining sperm oxidative stress. These findings suggest that MiOXSYS and OxiSperm II systems for the measurement of sperm oxidative stress may have limited diagnostic potential.
ISSN:2047-2919
2047-2927
DOI:10.1111/andr.13356